{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:40:08Z","timestamp":1776994808099,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07985-7","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:48:48Z","timestamp":1773740928000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinicopathological observation and initial exploration of characteristic biomarkers in breast apocrine carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Minmin","family":"Yu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuming","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinqian","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangshang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoqiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"issue":"6","key":"7985_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.4048\/jbc.2022.25.e46","volume":"25","author":"HJ Lee","year":"2022","unstructured":"Lee HJ, Kang SW, Lee JE, et al. Malignant apocrine lesions of the breast: multimodality imaging findings and biologic features . J Breast Cancer. 2022;25(6):513\u201321.","journal-title":"J Breast Cancer"},{"issue":"2","key":"7985_CR2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast . Histopathology. 2020;77(2):181\u201385.","journal-title":"Histopathology"},{"key":"7985_CR3","volume-title":"Rosen\u2019s breast pathology","author":"SA Hoda","year":"2021","unstructured":"Hoda SA, Brogi E, Koerner FC, Rosen PP. Rosen\u2019s breast pathology. 5th. Philadelphia, PA: Wolters Kluwer; 2021.","edition":"5th"},{"issue":"8","key":"7985_CR4","first-page":"1664","volume":"38","author":"J Jia","year":"2018","unstructured":"Jia J, Liu J, Shi X, et al. Simple breast apocrine carcinoma and its precancerous lesions: a case report of 10 cases. J Educ Chang Clin Pathological Res. 2018;38(8):1664\u201374.","journal-title":"J Educ Chang Clin Pathological Res"},{"issue":"2","key":"7985_CR5","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1524-4741.2007.00548.x","volume":"14","author":"K Tanaka","year":"2008","unstructured":"Tanaka K, Imoto S, Wada N, et al. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients . The Breast J. 2008;14(2):164\u201368.","journal-title":"The Breast J"},{"key":"7985_CR6","doi-asserted-by":"crossref","unstructured":"Vranic S, Gatalica Z. An update on the molecular and Clinical characteristics of apocrine carcinoma of the breast . Clin Breast Cancer. 2022;22(4):e576\u201385.","DOI":"10.1016\/j.clbc.2021.12.009"},{"issue":"1","key":"7985_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/IJPM.IJPM_520_20","volume":"65","author":"D Goel","year":"2022","unstructured":"Goel D, Maurya M K, Ramakant P. Apocrine carcinoma of breast: A rare case report . Indian J Pathol Microbiol. 2022;65(1):221\u201323.","journal-title":"Indian J Pathol Microbiol"},{"issue":"5","key":"7985_CR8","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/hupa.2001.24327","volume":"32","author":"C Leal","year":"2001","unstructured":"Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers . Hum Pathol. 2001;32(5):487\u201393.","journal-title":"Hum Pathol"},{"issue":"1","key":"7985_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jclinpath-2018-205484","volume":"72","author":"C D\u2019arcy","year":"2019","unstructured":"D\u2019arcy C, Quinn C. Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast . J Clin Pathol. 2019;72(1):1\u20136.","journal-title":"J Clin Pathol"},{"issue":"8","key":"7985_CR10","first-page":"813","volume":"7","author":"FA Tavassoli","year":"1994","unstructured":"Tavassoli FA, Norris H J. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases . Mod Pathol: Off J U States Can Acad Pathol, Inc. 1994;7(8):813\u201318.","journal-title":"Mod Pathol: Off J U States Can Acad Pathol, Inc"},{"issue":"1","key":"7985_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2559.2007.02888.x","volume":"52","author":"O\u2019malley F","year":"2008","unstructured":"O\u2019malley F, Bane A. An update on apocrine lesions of the breast . Histopathology. 2008;52(1):3\u201310.","journal-title":"Histopathology"},{"issue":"3","key":"7985_CR12","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1365-2559.2009.03223.x","volume":"54","author":"G Elayat","year":"2009","unstructured":"Elayat G, Selim A G, Wells C A. Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast . Histopathology. 2009;54(3):348\u201354.","journal-title":"Histopathology"},{"issue":"4","key":"7985_CR13","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/ajcp\/94.4.371","volume":"94","author":"AD Abati","year":"1990","unstructured":"Abati AD, Kimmel M, Rosen P P. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases . Am J Clin Pathol. 1990;94(4):371\u201377.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"7985_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.breast.2004.06.003","volume":"14","author":"H Japaze","year":"2005","unstructured":"Japaze H, Emina J, Diaz C, et al. \u2018Pure\u2019 invasive apocrine carcinoma of the breast: a new clinicopathological entity? Breast (Edinburgh, Scotl). 2005;14(1):3\u201310.","journal-title":"Breast (Edinburgh, Scotl)"},{"issue":"10","key":"7985_CR15","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1007\/s43032-024-01676-8","volume":"31","author":"SS Bahreiny","year":"2024","unstructured":"Bahreiny SS, Ahangarpour A, Rajaei E, Sharifani MS, Aghaei M. Meta-analytical and meta-regression evaluation of subclinical Hyperthyroidism\u2019s effect on male reproductive Health: hormonal and seminal perspectives. Reprod. Sci. 2024, Oct;31(10):2957\u201371.","journal-title":"Reprod. Sci"},{"key":"7985_CR16","doi-asserted-by":"crossref","unstructured":"Bahreiny SS, Aghaei M, Dabbagh M R, et al. Exploring the relationship between ambient sulfur dioxide and semen quality parameters: a systematic review and meta-analysis.Asian. Pac J Reproduction. 2024;13(1).","DOI":"10.4103\/apjr.apjr_95_23"},{"issue":"1","key":"7985_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tjog.2023.10.003","volume":"63","author":"SS Bahreiny","year":"2024","unstructured":"Bahreiny SS, Bastani MN, Aghaei M, Dabbagh MR, Mahdizade AH. Circulating galectin-3 levels in women with polycystic ovary syndrome: a meta-analysis. Taiwan J Obstet Gynecol.2024, Jan;63(1):37\u201345.","journal-title":"Taiwan J Obstet"},{"issue":"3","key":"7985_CR18","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","volume":"35","author":"YZ Jiang","year":"2019","unstructured":"Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies . Cancer Cell. 2019;35(3):428\u201340.e5.","journal-title":"Cancer Cell"},{"key":"7985_CR19","doi-asserted-by":"crossref","unstructured":"Zhao S, Ma D, Xiao Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and Clinical relevance . The Oncologist. 2020;25(10):e1481\u201391.","DOI":"10.1634\/theoncologist.2019-0982"},{"issue":"6","key":"7985_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1593\/neo.08274","volume":"10","author":"A Naderi","year":"2008","unstructured":"Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer . Neoplasia. 2008;10(6):542\u201348.","journal-title":"Neoplasia"},{"key":"7985_CR21","doi-asserted-by":"crossref","unstructured":"Naderi A, Chia K M, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res: BCR. 2011;13(2):R36.","DOI":"10.1186\/bcr2858"},{"issue":"2","key":"7985_CR22","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1593\/neo.101324","volume":"13","author":"KM Chia","year":"2011","unstructured":"Chia KM, Liu J, Francis G D, et al. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer . Neoplasia. 2011;13(2):154\u201366.","journal-title":"Neoplasia"},{"issue":"29","key":"7985_CR23","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1038\/sj.onc.1208561","volume":"24","author":"P Farmer","year":"2005","unstructured":"Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis . Oncogene. 2005;24(29):4660\u201371.","journal-title":"Oncogene"},{"key":"7985_CR24","doi-asserted-by":"crossref","unstructured":"Guedj M, Marisa L, Reynies DE, A, et al. A refined molecular taxonomy of breast cancer. Oncogene. 2012;31(9):1196\u2013206.","DOI":"10.1038\/onc.2011.301"},{"issue":"2","key":"7985_CR25","first-page":"303","volume":"32","author":"C Constantinou","year":"2018","unstructured":"Constantinou C, Papadopoulos S, Karyda E, et al. Expression and Clinical significance of claudin-7, PDL-1, PTEN, c-kit, c-met, c-myc, ALK, CK5\/6, CK17, p53, EGFR, Ki67, p63 in triple-negative breast cancer-A single centre prospective observational study. In Vivo (Athens, Greece). 2018;32(2):303\u201311.","journal-title":"In Vivo (Athens, Greece)"},{"key":"7985_CR26","doi-asserted-by":"crossref","unstructured":"Yu S, Lu Y, Su A, et al. A CD10-OGP membrane peptolytic signaling axis in fibroblasts regulates lipid metabolism of cancer stem cells via SCD1. Adv Sci (Weinh). 2021;8(19):e2101848.","DOI":"10.1002\/advs.202101848"},{"key":"7985_CR27","doi-asserted-by":"crossref","unstructured":"Pietri E, Conteduca V, Andreis D, et al. Androgen receptor signaling pathways as a target for breast cancer treatment . Endocr-Relat Cancer. 2016;23(10):R485\u201398.","DOI":"10.1530\/ERC-16-0190"},{"key":"7985_CR28","doi-asserted-by":"crossref","unstructured":"Hackbart H, Cui X, Lee J S. Androgen receptor in breast cancer and its clinical implication . Transl Breast Cancer Res: J Focusing Transl Res Breast Cancer. 2023;4.","DOI":"10.21037\/tbcr-23-44"},{"issue":"6","key":"7985_CR29","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/1535-7163.MCT-20-0807","volume":"20","author":"JL Christenson","year":"2021","unstructured":"Christenson JL, O\u2019neill K, Williams M M, et al. Activity of combined androgen receptor antagonism and cell cycle inhibition in androgen receptor positive triple negative breast cancer . Mol Cancer Ther. 2021;20(6):1062\u201371.","journal-title":"Mol Cancer Ther"},{"key":"7985_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canlet.2020.11.045","volume":"502","author":"CE Mcaleese","year":"2021","unstructured":"Mcaleese CE, Choudhury C, Butcher N J, et al. Hypoxia-mediated drug resistance in breast cancers . Cancer Lett. 2021;502:189\u201399.","journal-title":"Cancer Lett"},{"issue":"4","key":"7985_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.15698\/cst2018.04.133","volume":"2","author":"X Meng","year":"2018","unstructured":"Meng X, Bozec A. New insights into the key role of HIF-1\u03b1 in IL-10-producing B cells . Cell Stress. 2018;2(4):94\u201395.","journal-title":"Cell Stress"},{"key":"7985_CR32","doi-asserted-by":"crossref","unstructured":"Wang Z, Zhu J, Liu Y, et al. Tumor-polarized GPX3(+) AT2 lung epithelial cells promote premetastatic niche formation . Proc. Natl. Acad. Sci. U. S. A. 2022;119(32):e2201899119.","DOI":"10.1073\/pnas.2201899119"},{"issue":"2","key":"7985_CR33","first-page":"565","volume":"197","author":"RA Fecher","year":"2016","unstructured":"Fecher RA, Horwath MC, Friedrich D, et al. Inverse correlation between IL-10 and HIF-1\u03b1 in macrophages infected with histoplasma capsulatum . J Retailing Immunol (Baltim, Md : 1950), 2016;197(2):565\u201379.","journal-title":"J Retailing Immunol (Baltim"},{"key":"7985_CR34","doi-asserted-by":"crossref","unstructured":"Nakamura H, Kukita Y, Kittaka N, Kusama H, Nakayama T, Tamaki Y, et al. Apocrine carcinoma of the breast: distinctive metabolic reprogramming and high-frequency PIK3CA mutations revealed by molecular and immunohistochemical analysis. Histopathology. 2025, Nov, 20.","DOI":"10.1111\/his.70024"},{"key":"7985_CR35","doi-asserted-by":"crossref","unstructured":"Meattini I, Pezzulla D, Saieva C, et al. Triple negative apocrine carcinomas as a distinct subtype of triple negative breast cancer: a Case-control study . Clin Breast Cancer. 2018;18(5):e773\u201380.","DOI":"10.1016\/j.clbc.2018.02.012"},{"issue":"9","key":"7985_CR36","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jamaoncol.2016.4975","volume":"3","author":"M Kono","year":"2017","unstructured":"Kono M, Fujii T, Lim B, et al. Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review . JAMA Oncol. 2017;3(9):1266\u201373.","journal-title":"JAMA Oncol"},{"issue":"5","key":"7985_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3348\/kjr.2015.16.5.1006","volume":"16","author":"KJ Seo","year":"2015","unstructured":"Seo KJ, An YY, Whang IY, et al. Sonography of invasive apocrine carcinoma of the breast in five cases . Korean J Radiol. 2015;16(5):1006\u201311.","journal-title":"Korean J Radiol"},{"issue":"1","key":"7985_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1007\/s10238-025-01751-7","volume":"25","author":"NS Sherafat","year":"2025","unstructured":"Sherafat NS, Keshavarz A, Mardi A, Mohammadiara A, Aghaei M, Aghebati-Maleki L, et al. Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective. Clin Exp Med. 2025, Jul, 8;25(1):238.","journal-title":"Clin Exp Med"},{"issue":"4","key":"7985_CR39","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.ejso.2017.11.027","volume":"44","author":"S Zhao","year":"2018","unstructured":"Zhao S, Ma D, Xiao Y, et al. Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis . Eur J Surg Oncol. 2018;44(4):420\u201328.","journal-title":"Eur J Surg Oncol"},{"issue":"31","key":"7985_CR40","doi-asserted-by":"publisher","first-page":"48905","DOI":"10.18632\/oncotarget.10211","volume":"7","author":"X Liu","year":"2016","unstructured":"Liu X, Yang Y, Feng X, et al. Early versus late distant metastasis and adjuvant chemotherapy alone versus both radiotherapy and chemotherapy in molecular apocrine breast cancer . Oncotarget. 2016;7(31):48905\u201317.","journal-title":"Oncotarget"},{"issue":"28","key":"7985_CR41","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1038\/sj.onc.1209415","volume":"25","author":"AS Doane","year":"2006","unstructured":"Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen . Oncogene. 2006;25(28):3994\u20134008.","journal-title":"Oncogene"},{"issue":"4","key":"7985_CR42","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.path.2025.08.009","volume":"18","author":"E Yang","year":"2025","unstructured":"Yang E, Hy W. Special subtypes of triple negative breast carcinoma. Surg Pathol Clin. 2025, Dec;18(4):665\u201373.","journal-title":"Surg Pathol Clin"},{"issue":"18","key":"7985_CR43","doi-asserted-by":"publisher","first-page":"7523","DOI":"10.1002\/cam4.2634","volume":"8","author":"W Wu","year":"2019","unstructured":"Wu W, Wu M, Peng G, Shi D, Zhang J. Prognosis in triple-negative apocrine carcinomas of the breast: a population-based study. Cancer Med. 2019, Dec;8(18):7523\u201331.","journal-title":"Cancer Med"},{"key":"7985_CR44","doi-asserted-by":"crossref","unstructured":"Ma J, et al. iProx: an integrated proteome resource. Nucleic Acids Res. 2019;47((D1)):D1211\u201317.","DOI":"10.1093\/nar\/gky869"},{"key":"7985_CR45","doi-asserted-by":"crossref","unstructured":"Chen T, et al. iProx in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 2021;50(D1):D1522\u201327.","DOI":"10.1093\/nar\/gkab1081"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07985-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07985-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07985-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:15:20Z","timestamp":1776993320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07985-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7985"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07985-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"5 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the ethical principles stipulated in the \u201cEthical Review Measures for Human Life Sciences and Medical Research (2023)\u201d issued by the National Health Commission, the \u201cGood Clinical Practice for Medical Devices (2022)\u201d issued by the National Medical Products Administration, the \u201cGood Clinical Practice for Drug Clinical Trials (2020)\u201d issued by the National Medical Products Administration, the \u201cHelsinki Declaration\u201d of the World Medical Association, and the \u201cInternational Ethical Guidelines for Human Biomedical Research\u201d of CIOMS, after approval by the Ethics Committee of the Affiliated Hospital of Shandong University of Traditional Chinese Medicine, this research has been approved to be carried out in accordance with the approved documents. The approval number is: (2024) lunshen NO. (057) - YJS. The written informed consent was obtained from the patients prior to their involvement in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate declaration"}},{"value":"The authors declare that this research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest. All the authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of competing interests"}}],"article-number":"579"}}